BACKGROUND & OBJECTIVE: The proliferating antigen Ki67 is an important biological marker in cell proliferation. This study was designed to investigate the expressions of Ki67, P53, vascular endothelial growth factor (VEGF),and C-erbB-2 in breast cancer tissue, and their correlations with cliniopathological significance. METHODS: The expressions of Ki67,p53,VEGF,and C-erbB-2 in 151 cases of breast cancer were assessed by immunohisto-chemistry, and their correlations with clinicopathological factors were statistically analyzed. RESULTS: The positive rate of Ki67 was 78.2%(113/151). The expression of Ki67 correlated with tumor stages (P< 0.05), but didn't relate to age, tumor size, and lymph node status (P >0.05). In addition,the expression of Ki76 had a positive correlation with the expressions of p53, and C-erbB-2 (P< 0.05), but not with the expression of VEGF (P >0.05). The co-expression of Ki67 and VEGF related to tumor size,and clinical stage (P< 0.05). CONCLUSIONS: The expression of Ki67 is an objective biological marker for estimating the occurrence and progression of breast cancer. Combined detection of Ki67 and VEGF may helps to judge the clinical stage of breast cancer.
BACKGROUND & OBJECTIVE: The proliferating antigen Ki67 is an important biological marker in cell proliferation. This study was designed to investigate the expressions of Ki67, P53, vascular endothelial growth factor (VEGF),and C-erbB-2 in breast cancer tissue, and their correlations with cliniopathological significance. METHODS: The expressions of Ki67,p53,VEGF,and C-erbB-2 in 151 cases of breast cancer were assessed by immunohisto-chemistry, and their correlations with clinicopathological factors were statistically analyzed. RESULTS: The positive rate of Ki67 was 78.2%(113/151). The expression of Ki67 correlated with tumor stages (P< 0.05), but didn't relate to age, tumor size, and lymph node status (P >0.05). In addition,the expression of Ki76 had a positive correlation with the expressions of p53, and C-erbB-2 (P< 0.05), but not with the expression of VEGF (P >0.05). The co-expression of Ki67 and VEGF related to tumor size,and clinical stage (P< 0.05). CONCLUSIONS: The expression of Ki67 is an objective biological marker for estimating the occurrence and progression of breast cancer. Combined detection of Ki67 and VEGF may helps to judge the clinical stage of breast cancer.